N/A N=1 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Local Control Rate — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Proton Therapy for Unresectable Cancer (CA) of Pancreas
Pancreatic Cancer
Primary: Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90…
N/A N=40 Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
Resectable Pancreatic Cancers
Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants
Phase 2 N=32 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
Phase 2 N=11 A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…
Phase 2 N=11 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=25 A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Pancreatic Cancer
Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 1 N=4 Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Phase 2 N=62 Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or…
Phase 2 N=32 Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Pancreatic Cancer Stage IVA
Primary: Conversion Rate of Inoperable to Operable
Phase 2 N=39 Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants
Phase 1 N=17 Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants
Phase 2 N=59 Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.
Phase 2 N=24 Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Phase 2 N=50 Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 5.7 months
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
Phase 2 N=13 Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Advanced Pancreatic Carcinoma · Locally Advanced Pancreatic Carcinoma · Metastatic Pancreatic Carcinoma
Primary: Tumor Response — 5; 3 Participants
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 1 N=21 Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=59 Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
Pancreatic Cancer
Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants
Phase 2 N=71 Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Two-year Disease Free Survival. — 26.1 percentage of patients
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 3 N=80 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 78.8 percentage of participants